Adjuvant chemotherapy provided survival benefit for stage T2N0 gastric cancer with high-risk factors

Year, pages: 2018, 592 - 598

The value of adjuvant chemotherapy in T2N0 gastric cancer (GC) remains controversial. The aim of this retrospective study is to define a high-risk subgroup of pathological T2N0 GC patients and examine the impact of adjuvant chemotherapy on overall survival (OS). A total of 225 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2002 and 2012 and 51/225 (22.7%) of these received adjuvant chemotherapy. Multivariate Cox regression identified tumor location in the Upper1/3 of the stomach (p<0.001), larger tumor diameter (p=0.013), lymphatic and/or blood vessel invasion (p=0.001), and perineural invasion (p<0.001) as independent risk factors associated with significantly decreased OS. There were 141 patients with at least one risk factor who were defined in the high-risk subgroup. After propensity score matching, there was a significant trend toward improved OS (P=0.042) with adjuvant chemotherapy in the high-risk subgroup. In conclusion, we identified a high-risk subgroup of T2N0 GC with at least one of the independent risk factor listed above, and we found that adjuvant chemotherapy significantly improved OS for this subgroup.

Wang, Z., Yan, J., Hu, W., Zhang, J., Huo, B. 2018. Adjuvant chemotherapy provided survival benefit for stage T2N0 gastric cancer with high-risk factors. In NEOPLASMA, vol. 65, no.4, pp. 592-598. 0028-2685.

Wang, Z., Yan, J., Hu, W., Zhang, J., Huo, B. (2018). Adjuvant chemotherapy provided survival benefit for stage T2N0 gastric cancer with high-risk factors. NEOPLASMA, 65(4), 592-598. 0028-2685.